» Articles » PMID: 24173372

Cryptotanshinone Induces G1 Cell Cycle Arrest and Autophagic Cell Death by Activating the AMP-activated Protein Kinase Signal Pathway in HepG2 Hepatoma

Overview
Journal Apoptosis
Publisher Springer
Date 2013 Nov 1
PMID 24173372
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

AMP-activated protein kinase (AMPK) performs a pivotal function in energy homeostasis via the monitoring of intracellular energy status. Once activated under the various metabolic stress conditions, AMPK regulates a multitude of metabolic pathways to balance cellular energy. In addition, AMPK also induces cell cycle arrest or apoptosis through several tumor suppressors including LKB1, TSC2, and p53. LKB1 is a direct upstream kinase of AMPK, while TSC2 and p53 are direct substrates of AMPK. Therefore, it is expected that activators of AMPK signal pathway might be useful for treatment or prevention of cancer. In the present study, we report that cryptotanshinone, a natural compound isolated from Salvia miltiorrhiza, robustly activated AMPK signaling pathway, including LKB1, p53, TSC2, thereby leading to suppression of mTORC1 in a number of LKB1-expressing cancer cells including HepG2 human hepatoma, but not in LKB1-deficient cancer cells. Cryptotanshinone induced HepG2 cell cycle arrest at the G1 phase in an AMPK-dependent manner, and a portion of cells underwent apoptosis as a result of long-term treatment. It also induced autophagic HepG2 cell death in an AMPK-dependent manner. Cryptotanshinone significantly attenuated tumor growth in an HCT116 cancer xenograft in vivo model, with a substantial activation of AMPK signal pathways. Collectively, we demonstrate for the first time that cryptotanshinone harbors the therapeutic potential for the treatment of cancer through AMPK activation.

Citing Articles

AMPK Alchemy: Therapeutic Potentials in Allergy, Aging, and Cancer.

Pokhrel R, Acharya S, Mishra S, Gu Y, Manzoor U, Kim J Biomol Ther (Seoul). 2024; 32(2):171-182.

PMID: 38346909 PMC: 10902700. DOI: 10.4062/biomolther.2023.222.


Study on the Intervention Mechanism of Cryptotanshinone on Human A2780 Ovarian Cancer Cell Line Using GC-MS-Based Cellular Metabolomics.

Wang T, Yin S, Gu J, Li J, Zhang M, Shan J Pharmaceuticals (Basel). 2023; 16(6).

PMID: 37375808 PMC: 10304112. DOI: 10.3390/ph16060861.


Cryptotanshinone attenuates LPS-induced acute lung injury by regulating metabolic reprogramming of macrophage.

Ye Z, Wang P, Feng G, Wang Q, Liu C, Lu J Front Med (Lausanne). 2023; 9:1075465.

PMID: 36714100 PMC: 9880059. DOI: 10.3389/fmed.2022.1075465.


Recent advances of tanshinone in regulating autophagy for medicinal research.

Wu S, Zhao K, Wang J, Liu N, Nie K, Qi L Front Pharmacol. 2023; 13:1059360.

PMID: 36712689 PMC: 9877309. DOI: 10.3389/fphar.2022.1059360.


Bge. (Danshen) in the Treating Non-alcoholic Fatty Liver Disease Based on the Regulator of Metabolic Targets.

Liu J, Shi Y, Peng D, Wang L, Yu N, Wang G Front Cardiovasc Med. 2022; 9:842980.

PMID: 35528835 PMC: 9072665. DOI: 10.3389/fcvm.2022.842980.